Researchers at the University of Maryland in the U.S. have found that aspirin is a potential means of reducing the mortality rate from coronavirus by controlling complications.
The scientists conducted scientific work involving 412 infected patients. They were all hospitalized with symptoms of varying severity, Daily Mail reports.
314 of them did not receive aspirin during treatment. The remaining 98 took the drug within 24 hours of admission or 7 days before hospitalization. After that, the specialists analyzed the effect of aspirin on the need for artificial lung ventilation and admission to the intensive care unit. The mortality rate for all subjects was also calculated.
Researchers found that taking low-dose tablets daily can reduce the likelihood of getting into the intensive care unit or a room on a ventilator by more than 40%. In addition, it almost halves the risk of death from infection – by 47%.
It was found that among aspirin patients 35.7% of those infected needed to be connected to a ventilator, while in the second group, where no treatment was available, this figure was 48.4%.
The risk of need for intensive care when taking aspirin was also reduced by 12.2%.
Despite the positive results of the study, scientists insisted on conducting randomized controlled scientific work. This is necessary to establish a clearer link between aspirin use and the reduction of lung damage and mortality among those infected with coronavirus.
“If our discovery is confirmed, it will make aspirin the first widely available over-the-counter drug to reduce mortality in COVID-19 patients,” said research manager Dr. Jonathan Chow, associate professor of anesthesiology at UMSOM.